242 related articles for article (PubMed ID: 37835461)
21. Atypical Rearrangements in APL-Like Acute Myeloid Leukemias: Molecular Characterization and Prognosis.
Guarnera L; Ottone T; Fabiani E; Divona M; Savi A; Travaglini S; Falconi G; Panetta P; Rapanotti MC; Voso MT
Front Oncol; 2022; 12():871590. PubMed ID: 35494081
[TBL] [Abstract][Full Text] [Related]
22. Does leukocytosis remain a predictive factor for survival outcomes in patients with acute promyelocytic leukemia receiving ATRA plus a chemotherapy-based regimen? A prospective multicenter analysis from TALWG.
Kungwankiattichai S; Owattanapanich W; Rattanathammethee T; Rattarittamrong E; Chanswangphuwana C; Polprasert C; Limvorapitak W; Saengboon S; Niparuck P; Puavilai T; Julamanee J; Saelue P; Wanitpongpun C; Prayongratana K; Sriswasdi C; Nakhakes C
Hematology; 2023 Dec; 28(1):2191462. PubMed ID: 36951362
[TBL] [Abstract][Full Text] [Related]
23. Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia.
Fathi AT; Stein EM; DiNardo CD; Levis MJ; Montesinos P; de Botton S
Am J Hematol; 2021 Jun; 96(6):735-746. PubMed ID: 33625753
[TBL] [Abstract][Full Text] [Related]
24. Acute promyelocytic leukemia: recent advances in diagnosis and management.
Lo-Coco F; Ammatuna E; Montesinos P; Sanz MA
Semin Oncol; 2008 Aug; 35(4):401-9. PubMed ID: 18692690
[TBL] [Abstract][Full Text] [Related]
25. Evolving Chemotherapy Free Regimens for Acute Promyelocytic Leukemia.
Kulkarni U; Mathews V
Front Oncol; 2021; 11():621566. PubMed ID: 33718181
[TBL] [Abstract][Full Text] [Related]
26. Acute Respiratory Distress Syndrome in a Patient With Acute Promyelocytic Leukemia: Overlapping Between Differentiation Syndrome and COVID-19.
Sui J; Kelmenson D; Hu S; Cao L
J Hematol; 2021 Oct; 10(5):217-220. PubMed ID: 34804311
[TBL] [Abstract][Full Text] [Related]
27. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
28. [Acute promyelocytic leukemia: state-of-the-art management].
Asou N
Rinsho Ketsueki; 2018; 59(6):725-734. PubMed ID: 29973452
[TBL] [Abstract][Full Text] [Related]
29. Effects of peripheral blood leukocyte count and tumor necrosis factor-alpha on early death in acute promyelocytic leukemia.
Wen J; Xu F; Zhou Q; Shi L; Liu Y; Yue J; Zhang Y; Liang X
BMC Cancer; 2023 Jan; 23(1):27. PubMed ID: 36611025
[TBL] [Abstract][Full Text] [Related]
30. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
Xu SN; Chen JP; Liu JP; Xia Y
Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733
[TBL] [Abstract][Full Text] [Related]
31. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Grimwade D; Mistry AR; Solomon E; Guidez F
Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
[TBL] [Abstract][Full Text] [Related]
32. [Acute renal failure in the transretinoic syndrome].
Sastre A; Gago E; Baños M; Gómez E
Nefrologia; 2007; 27(2):184-90. PubMed ID: 17564563
[TBL] [Abstract][Full Text] [Related]
33. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome.
Luesink M; Pennings JL; Wissink WM; Linssen PC; Muus P; Pfundt R; de Witte TJ; van der Reijden BA; Jansen JH
Blood; 2009 Dec; 114(27):5512-21. PubMed ID: 19828696
[TBL] [Abstract][Full Text] [Related]
34. Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low-middle-income country.
Lins MM; Mello MJG; Ribeiro RC; De Camargo B; de Fátima Pessoa Militão de Albuquerque M; Thuler LCS
Ann Hematol; 2019 Jun; 98(6):1403-1411. PubMed ID: 30915498
[TBL] [Abstract][Full Text] [Related]
35. Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation.
van Gils N; Verhagen HJMP; Smit L
Exp Hematol; 2017 Aug; 52():12-23. PubMed ID: 28456748
[TBL] [Abstract][Full Text] [Related]
36. All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.
Liu X; Chen J; Yu S; Yan L; Guo H; Dai J; Zhang W; Zhu J
Cell Death Dis; 2017 May; 8(5):e2782. PubMed ID: 28492552
[TBL] [Abstract][Full Text] [Related]
37. Real-world assessment of isocitrate dehydrogenase inhibitor-associated differentiation syndrome.
Megherea O; Janes C; Kowalski A; Baron J; Ahn E; Soule A; Newman M
Leuk Lymphoma; 2021 Dec; 62(13):3219-3225. PubMed ID: 34313176
[TBL] [Abstract][Full Text] [Related]
38. The impact of ICAM-1, CCL2 and TGM2 gene polymorphisms on differentiation syndrome in acute promyelocytic leukemia.
Mohammadzadeh Z; Omidkhoda A; Chahardouli B; Hoseinzadeh G; Moghaddam KA; Mousavi SA; Rostami S
BMC Cancer; 2021 Jan; 21(1):46. PubMed ID: 33422029
[TBL] [Abstract][Full Text] [Related]
39. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
[TBL] [Abstract][Full Text] [Related]
40. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
Lo-Coco F; Hasan SK
Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
